There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kineta (KA – Research Report), Eli Lilly & Co (LLY – Research Report) and Iovance Biotherapeutics (IOVA – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co today and set a price target of $680.00. The company’s shares closed last Monday at $630.88, close to its 52-week high of $647.73.
According to TipRanks.com, Gould is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $659.67 average price target, implying a 4.7% upside from current levels. In a report issued on January 11, Morgan Stanley also maintained a Buy rating on the stock with a $763.00 price target.
Iovance Biotherapeutics (IOVA)
In a report released yesterday, Peter Lawson from Barclays assigned a Buy rating to Iovance Biotherapeutics, with a price target of $18.00. The company’s shares closed last Monday at $8.08.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Iovance Biotherapeutics with a $21.10 average price target, implying a 168.4% upside from current levels. In a report issued on January 16, Mizuho Securities also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KA:
- Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
- Kineta provides update on ongoing Phase 1/2 VISTA-101 trial of KVA12123
- Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
- Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
- Kineta publishes preclinical data on KVA12123
